Indications
Veoza is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
Composition
- Active substance
- fezolinetant
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Veoza
- Active substance
- fezolinetant
- ATC code
- G02CX06
- Therapeutic area
- Menopause, Hot Flashes
- Marketing authorisation holder
- Astellas Pharma Europe B.V.
- Status
- Authorised
- EU authorisation
- 7 Dec 2023